Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.OJtTHmzH.js ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
Texas Instruments falls after the chip maker’s first-quarter earnings forecast misses estimates, and Boeing declines after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback